Table 1 Antibody-based therapies approved or under review for haematological or transplant-related disorders
From: Worked to the bone: antibody-based conditioning as the future of transplant biology
International non-proprietary name | Brand name | Target | Format | Conjugated/unconjugated | Indication first approved or reviewed | First US approval year |
|---|---|---|---|---|---|---|
Muromonab-CD3 | Orthoclone Okt3 | CD3 | Full-length antibody | Unconjugated | Reversal of kidney transplant rejection | 1986 |
Abciximab | Reopro | GPIIb/IIIa | Fab | Unconjugated | Prevention of blood clots in angioplasty | 1994 |
Basiliximab | Simulect | IL-2R | Full-length antibody | Unconjugated | Prevention of kidney transplant rejection | 1998 |
Rituximab | MabThera, Rituxan | CD20 | Full-length antibody | Unconjugated | NHL | 1997 |
Trastuzumab | Herceptin | HER2 | Full-length antibody | Unconjugated | Breast cancer | 1998 |
Gemtuzumab ozogamicin | Mylotarg | CD33 | Full-length antibody | ADC | AML | 2017; 2000 |
Alemtuzumab | Lemtrada; MabCampath, Campath-1H | CD52 | Full-length antibody | Unconjugated | Multiple sclerosis; CML | 2014; 2001 |
Ibritumomab tiuxetan | Zevalin | CD20 | Full-length antibody | Radio-immunotherapeutic | NHL | 2002 |
Tositumomab-I131 | Bexxar | CD20 | Full-length antibody | Radio-immunotherapeutic | NHL | 2003 |
Eculizumab | Soliris | C5 | Full-length antibody | Unconjugated | Paroxysmal nocturnal haemoglobinuria | 2007 |
Ofatumumab | Arzerra | CD20 | Full-length antibody | Unconjugated | CLL | 2009 |
Brentuximab vedotin | Adcetris | CD30 | Full-length antibody | ADC | HL, sALCL | 2011 |
Obinutuzumab | Gazyva, Gazyvaro | CD20 | Full-length antibody | Unconjugated | CLL | 2013 |
Idarucizumab | Praxbind | Dabigatran | Fab | Unconjugated | Reversal of dabigatran-induced anticoagulation | 2015 |
Blinatumomab | Blincyto | CD19, CD3 | Tandem scFv | Unconjugated | ALL | 2014 |
Daratumumab | Darzalex | CD38 | Full-length antibody | Unconjugated | MM | 2015 |
Elotuzumab | Empliciti | SLAMF7 | Full-length antibody | Unconjugated | MM | 2015 |
Inotuzumab ozogamicin | BESPONSA | CD22 | Full-length antibody | ADC | ALL | 2017 |
Emicizumab | Hemlibra | Factor Ixa, X | Full-length antibody | Unconjugated | Haemophilia A | 2017 |
Ravulizumab | Ultomiris | C5 | Full-length antibody | Unconjugated | Paroxysmal nocturnal haemoglobinuria | 2018 |
Moxetumomab pasudotox | Lumoxiti | CD22 | dsFv immunotoxin | Immunotoxin | Hairy cell leukaemia | 2018 |
Crizanlizumab | Adakveo | CD62 | Full-length antibody | Unconjugated | Sickle cell disease | 2019 |
Polatuzumab vedotin | Polivy | CD79b | Full-length antibody | ADC | DLBCL | 2019 |
Isatuximab | Sarclisa | CD38 | Full-length antibody | Unconjugated | MM | 2020 |
Belantamab mafodotin | BLENREP | BCMA | Full-length antibody | ADC | MM | 2020 |
Tafasitamab | Monjuvi, Minjuvi | CD19 | Full-length antibody | Unconjugated | DLBCL | 2020 |
Loncastuximab tesirine | Zynlonta | CD19 | Full-length antibody | ADC | DLBCL | 2021 |
Narsoplimab | (Pending) | MASP-2 | Full-length antibody | Unconjugated | HSCT-Associated thrombotic microangiopathies | In review |
Ublituximab | (Pending) | CD20 | Full-length antibody | Unconjugated | CLL | In review |
Teclistamab | (Pending) | BCMA, CD3 | Full-length antibody | Unconjugated | MM | In review |